Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8407096 | 0.85 | L3MBTL1 (0.37) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL920758 | 0.85 | L3MBTL1 (0.40) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL921597 | 0.84 | L3MBTL1 (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL921028 | 0.83 | CYP1A2 (0.49) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL920464 | 0.83 | L3MBTL1 (0.46) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL920097 | 0.83 | L3MBTL1 (0.42) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL919613 | 0.82 | L3MBTL1 (0.45) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL919867 | 0.81 | L3MBTL1 (0.45) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL919818 | 0.81 | L3MBTL1 (0.45) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL920954 | 0.81 | L3MBTL1 (0.45) | L3MBTL1CYP1A2CYP2D6CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| US-8748599-B2 | Cyclic triazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2014-06-10 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| US-20120135992-A1 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2012-05-31 | — | — | US | claimed |
| EP-2451806-A2 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2012-05-16 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| WO-2011072064-A1 | S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | claimed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | claimed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-06-22 | — | — | US | claimed |
| EP-1585481-A2 | PYRAZOLOPYRIMIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-19 | — | — | EP | claimed |
| WO-2004064721-A2 | A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2004-08-05 | — | — | WO | claimed |
| JP-2002536440-A | — | — | 2002-10-29 | — | — | JP | claimed |
| US-6448259-B1 | CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY | NEUROGEN CORPORATION | 2002-09-10 | — | — | US | claimed |
| EP-1155007-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. Searle LLC (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2000047568-A2 | 1,2-BENZOTHIAZEPINES FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES | G.D. SEARLE LLC (US) | 2000-08-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135992-A1 | CYCLIC TRIAZO SODIUM CHANNEL BLOCKERS | SCN5A, SCN1B, KCNH2 | L3MBTL1 2496/4885CYP1A2 1010/4885CYP2D6 1996/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | L3MBTL1 4431/4885CYP1A2 1710/4885CYP2D6 1115/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 3563/4885CYP1A2 2270/4885CYP2D6 1847/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 3563/4885CYP1A2 2270/4885CYP2D6 1847/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 2990/4885CYP1A2 1024/4885CYP2D6 818/4885 |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | KCNJ2, KCNN2, KCNH2 | L3MBTL1 3439/4885CYP1A2 303/4885CYP2D6 203/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | L3MBTL1 2990/4885CYP1A2 1024/4885CYP2D6 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.